Can ferric carboxymaltose be administered to an 80‑year‑old patient with hemoglobin 8 g/dL anemia and an estimated glomerular filtration rate of 56 mL/min/1.73 m² with normal urea and creatinine values?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Yes, ferric carboxymaltose can be safely administered to this patient and is specifically indicated for this clinical scenario.

This 80-year-old patient with hemoglobin 8 g/dL and eGFR 56 mL/min/1.73 m² is an ideal candidate for intravenous ferric carboxymaltose (FCM), as the drug has been extensively studied and proven safe and effective in elderly patients with chronic kidney disease and anemia. 1

Evidence Supporting Use in This Patient Population

FDA-Approved Indication for CKD Patients

The FDA label specifically includes patients with non-dialysis dependent chronic kidney disease (ND-CKD) and anemia 1. The pivotal REPAIR-IDA trial enrolled patients with:

  • Mean age 67 years (range 19-101 years)
  • Hemoglobin ≤11.5 g/dL
  • eGFR consistent with CKD stages 3-5

Your patient's eGFR of 56 mL/min/1.73 m² (CKD stage 3a) falls well within the studied population 1.

Safety in Elderly Patients

Multiple studies confirm excellent safety in geriatric populations:

  • A retrospective cohort of patients aged 65-101 years showed FCM was well tolerated with only mild/moderate adverse events (most commonly transient liver enzyme elevations in 13.2%) 2
  • A non-interventional study of 264 geriatric patients (mean age 76.9 years, range 70-90) demonstrated no severe adverse reactions 3
  • The REPAIR-IDA trial included patients up to 101 years old without age-related safety concerns 1

Renal Function Considerations

Importantly, FCM may actually improve renal function rather than harm it:

  • In ND-CKD patients treated with 1000 mg FCM, eGFR increased by 1.55 ± 6.86 mL/min/m² (p=0.049) over 24 weeks 4
  • The FAIR-HF trial showed FCM was associated with eGFR improvement of 2.98 mL/min/1.73 m² at 24 weeks compared to placebo (p=0.039) 5
  • This renal benefit appears related to correction of anemia and improvement in systemic hemodynamics 6

Dosing and Administration Protocol

Recommended approach for this patient:

  1. Calculate total iron deficit using the Ganzoni formula or simplified dosing:

    • For Hb 8 g/dL with body weight ~70 kg: approximately 1000-1500 mg total iron needed

  2. Administer FCM as follows:

    • First dose: 750 mg (or up to 1000 mg if using European protocols) diluted in 100 mL normal saline
    • Infusion time: 15-30 minutes 7
    • Second dose (if needed): 750 mg given 7 days after first dose 1

  3. Monitoring protocol:

    • Start infusion slowly and observe for several minutes for acute reactions 7
    • Check hemoglobin at 4 weeks post-treatment
    • Reassess at 8-12 weeks to confirm adequate response
    • Monitor serum phosphate levels, particularly if repeat dosing needed 7

Important Caveats and Precautions

Hypophosphatemia Risk

FCM is associated with treatment-emergent hypophosphatemia and should be monitored, especially with:

  • Repeat infusions
  • Total doses >1750 mg
  • Baseline phosphorus <3.05 mg/dL 7, 8

However, this should not preclude initial treatment in this patient who requires iron repletion.

Normal Urea and Creatinine Values

The fact that urea and creatinine are "normal" despite eGFR 56% suggests:

  • Early CKD stage 3a
  • Possibly age-related decline in GFR with preserved tubular function
  • This does NOT contraindicate FCM use - the eGFR is the relevant parameter, and this patient falls within the studied range 1

Advantages Over Oral Iron in This Patient

Given the CKD context, FCM is superior to oral iron:

  • 75.5% response rate with FCM vs. 11.7% with oral iron in ND-CKD patients 9
  • Better tolerability (2.7% treatment-related adverse events vs. 26.2% with oral iron) 9
  • Functional iron deficiency in CKD renders oral iron ineffective due to elevated hepcidin 3

Expected Outcomes

Based on the REPAIR-IDA trial data 1:

  • Hemoglobin increase: Expect 1.1 g/dL mean increase by 8 weeks
  • Ferritin increase: Mean 734.7 ng/mL increase
  • Transferrin saturation: Mean 30% increase
  • Quality of life: Significant improvement in physical and psychological domains 8

Bottom line: Proceed with FCM administration using standard dosing (750-1000 mg initially, repeat in 7 days if needed), monitor for hypophosphatemia, and reassess hematologic response at 4-8 weeks. 7, 1

References

9
Research

A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2011

Related Questions

What are the possible adverse reactions to ferrelectit (ferrous iron) and how should they be managed?
Is it appropriate to prescribe ferrous sulfate 325 mg (equivalent to 65 mg elemental iron) for an adult with low ferritin?
Can intravenous iron carboxymaltose be administered through an arteriovenous fistula?
Can iron deficiency with normal ferritin levels cause an elevated platelet count?
What is the management approach for an 84-year-old male with iron deficiency anemia, normal ferritin levels, and normal Total Iron-Binding Capacity (TIBC) levels?
What are the possible causes of immediate watery diarrhea triggered by any food or drink, and what urgent management steps should be taken?
In a patient one month after hemorrhoidectomy who developed tightness and pain on defecation two weeks post‑operatively, with examination under anesthesia (EUA) and a Hegar dilator size 16 showing no anal stenosis but persistent difficulty defecating and a per‑rectal exam revealing anal sphincter spasm, what are the possible causes and treatment options?
How should a tortuous left mid-to-distal carotid artery identified on carotid ultrasound be managed?
What does the FibroSure NASH test assess for hepatic steatosis?
Can compression stockings be used during initiation of furosemide therapy for a patient with grade 2 peripheral edema when all vascular studies are normal?
For a 54-year-old woman with low-grade ductal carcinoma in situ of the breast, should immunohistochemistry (estrogen receptor, progesterone receptor, HER2) be performed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.